Kornimate/medical-research-clean huggingface dataset:
prevalence of histoplasmosis in hiv + patients with a rapid diagnostic test in west indies

Conditions: HIV

Summary: histoplasma capsulatum var. capsulatum histoplasmosis is the leading cause of acquired immunodeficiency syndrome (aids) and death in french guiana and probably in the amazon. the diagnosis of this disease requires invasives procedures, laboratory performance, and delays up to several weeks. the mycotic diseases branch of the centers for disease control and prevention (cdc) has established a rapid, sensitive and specific elisa test for blood and urine samples that looks interesting in endemic areas, particularly in developing countries. the study aims to measure the proportion of hiv-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for histoplasma capsulatum var. capsulatum.


Eligibility criteria:
inclusion criteria: * adult (aged 18 or over). * patient seen while hospitalized or in outpatient awaiting hospitalization. * hiv1 or hiv2 infection confirmed by techniques validated in france and in suriname, either before the episode considered, or discovered concomitantly. * patient presenting at least one of the three followings items: an alteration of their general condition (with a grade 1 according to the who performance status scale) and/or a fever and/or symptoms suggestive of an infectious syndrome. * medical prescription for the collection of blood and urine specimens to test for an infectious agent within 7 days following admission to the hospital. * written consent to participate in the study obtained. exclusion criteria: * refusal to participate in the study. * patient in a critical condition that doesn't allow physicians to get an informed consent without a legal representative to represent him and sign a consent form for the patient participation in the study. * ongoing antifungal treatment or antifungal treatment stopped during the month preceding the inclusion date (topic antifungal therapy not considered at this point). * patient in detention at the time of admission to the hospital.

Keywords: hiv histoplasmosis histoplasma capsulatum var.capsulatum elisa test
reliability and validity of fibser, star-p, hea scale the reliability and validity of chinese version of fibser, star-p, hea scale in depression assessment

Conditions: Depression

Summary: according to the survey of the world health organization, the number of patients with depression in the world has reached 350 million, has becoming the primary cause of disability and the main disease burden worldwide. in order to better dealing with adverse reactions, improving the doctor-patient relationship and optimizing the treatment cost, fibser, star-p and hea health economics follow-up evaluation scale are selected as simple and quick evaluation scales to evaluate the influence, doctor-patient relationship and social and economic benefits after drug treatment in clinical treatment. at present, the reliability and validity of fibser, star-p and hea scales will be verified the reliability and validity of the above three scales in depressive disorder, aiming at enriching the treatment of depressive patients based on assessment, thus improving the compliance of medication for depressive disorder, improving the doctor-patient relationship and reducing the total burden of social diseases.

in this study, the reliability and validity of fibser scale, doctor-patient relationship scale-patient edition (star-p) and hea in chinese population will be verified to increase the diversity and selectivity of domestic assessment tools. this study includes two steps. 1. baseline: demographic data, ham-d, ham-a, ymrs, drug side effects scale：fibser, tess； doctor-patient relationship scale ：star-p, pdrq-15；health economics follow-up evaluation scale ：sds and hea were evaluated. 2. follow-up (4 weeks): ham-d, ham-a, ymrs, fibser, star-p and hea scale in order to verify the reliability of retest.

Eligibility criteria:
inclusion criteria: * case group: 1. the subjects were psychiatric outpatients and inpatients who were able and willing to provide informed consent. 2. men or women aged between 18 and 65, with junior high school education or above. 3. according to dsm-5 criteria, patients diagnosed with depressive disorder. 4. the total score of hamilton depression scale (ham-d) was ≥7 and the total score of young mania scale (ymrs) was ≤5. 5. subjects were treated with antidepressants at least two weeks before the study visit, all of them were ssris. control group: 1）did not meet the diagnostic criteria of any axis i in dsm-5. 2）18-65 years old, with junior high school education or above. 3）willing to participate in this study, and the subjects signed the informed consent form. exclusion criteria: - 1）severe drug allergy. 2）suffering from some serious physical diseases adversely affects the validity of neuropsychological test data. 3）serious negative suicide concept.

Keywords: fibser star-p hea scale
asthma link: a real world application of school supervised asthma therapy

Conditions: Childhood Asthma

Summary: the goal of this study is to assess the feasibility of a clinical trial to evaluate the impact and process of deploying school-supervised asthma therapy in a real-world setting for children with poorly controlled asthma (aged 6-17 years).

the proposed 4-site pilot cluster randomized controlled trial will assess the feasibility of conducting a clinical trial of asthma link, a real-world school-supervised asthma therapy program. we will compare the impact of asthma link deployed in 2 pediatric practice sites versus enhanced usual care deployed in 2 comparator sites, with 18 parent-child dyads enrolled per site (n=72 dyads). primary trial outcomes will be participant recruitment, retention, and intervention fidelity. secondary trial outcomes will be differences in the frequency of asthma symptoms, emergency department visits, hospital admissions, courses of oral corticosteroids, spirometry values, medication adherence and school absences between intervention and enhanced usual care sites at 3, 6 and 12 month follow up. additionally we will assess process outcomes (acceptability, adoption, costs, sustainability).

Eligibility criteria:
study inclusion/exclusion criteria: child inclusion criteria: * meet the eligibility criteria for asthma link (as described below) * enrolled in asthma link (if randomized to the asthma link condition) * able and willing to provide informed assent child exclusion criteria: * unable or unwilling to provide informed assent * diagnosis of a serious co-morbid illness during the past 5 years * developmental delay that would prevent study participation. * planning on moving from primary residence or moving outside of the school district in the next 1 year * a sibling to a child participating in this study parent inclusion criteria: * parent/guardian to patient * 18 years or older * able to understand and communicate in english or spanish * able and willing to provide informed consent. parent exclusion criteria: * adults lacking capacity * prisoners medical provider, school nurse, asthma champion inclusion criteria: • able and willing to provide informed consent medical provider, school nurse, asthma champion exclusion criteria: • unable or unwilling to provide informed consent child eligibility for children enrolled in asthma link: * children aged 6-17 years (enrolled in grade 1-12) * prescribed daily inhaled corticosteroid (ics) for asthma * 1 or more courses of oral steroids in the past 2 years or 1 or more hospitalizations or ed visits for asthma in the past 2 years or 1 or more sick visits for asthma in the past year or asthma control test (act) score \<19 * parent/child report of poor ics adherence on adherence checklist- i.e. child or parent says "yes" when provider asks if they have difficulty remembering to take their medication or if they regularly take medication holidays or breaks * able and willing to assent * parental permission * english or spanish speaking

Keywords: asthma childhood asthma stakeholder engagement medication adherence school-supervised asthma therapy real-world pragmatic trial
the long term outcomes of micronutrient antioxidant supplementation in patients with chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: this is a anonymised case note study looking at the long term outcomes of patients with chronic pancreatitis on micro nutrient antioxidant treatment.

chronic pancreatitis is the medical term for chronic inflammation of the pancreas. this illness is associated with long-term abdominal pain. in the 1980s it was proposed that chronic pancreatitis was due to a deficiency of protective "antioxidants" in the pancreas and on this basis antioxidant therapy was introduced. this therapy was highly controversial until a large randomised trial of antioxidant therapy in chronic pancreatitis, undertaken in manchester showed that 6 months intervention with antioxidant therapy was not associated with any change in pain score or improvement in quality of life. antioxidant therapy is no longer used in modern day pancreatic practice. however, as with any study, the randomised trial raised some specific questions. first, does treatment for more than 6 months provide benefit? second, are there disease sub-types of chronic pancreatitis where antioxidant therapy may benefit? given the lack of contemporary use of antioxidant therapy, this question cannot be answered in a prospective study. however, the case records of the manchester royal infirmary contain information on antioxidant treatment in patients who received this therapy over a prolonged period. thus the aim of the present study is to review the case notes of patients given a discharge code from the manchester royal infirmary of chronic pancreatitis during the period 1st january 1990 to 1st january 1998 in order to assess whether there is a record of improvement in outcome. only the case notes will be reviewed and patients will be given an opportunity to opt out. the study accepts the limitations of assessing pain from clinical notes but also notes that more objective findings such as development of diabetes mellitus (a long term complication of chronic pancreatitis) can be assessed from the notes.

Eligibility criteria:
inclusion criteria: * patients with chronic pancreatitis treated with long term anti-oxidants exclusion criteria: * cancer, on trials
safety, tolerability and immunogenicity of v114 in healthy adults and infants (v114-004)

Conditions: Streptococcus Pneumoniae Infection; Pneumococcal Infections

Summary: this study is designed to assess the safety, tolerability, and immunogenicity of 5 different formulations of v114 in healthy adults and infants. adults only will be enrolled in period 1 and infants only will be enrolled in period 2; period 1 will complete prior to the start of period 2.


Eligibility criteria:
inclusion criteria infants: - healthy and able to attend all scheduled visits. adults: - highly unlikely to conceive from vaccination to 6 weeks after administration of the vaccine. exclusion criteria infants and adults: * prior administration of any pneumococcal vaccine, any non-live vaccine within 14 days, or any live vaccine within 30 days. * history of invasive pneumococcal disease. * known hypersensitivity to any vaccine component. * received systemic corticosteroids within 14 days of first vaccination. * known or suspected impairment of immune function. * febrile illness within 72 hours before vaccination. * received blood transfusion or blood products within 30 days. infants * mother has documented human immunodeficiency virus or is hepatitis b surface antigen positive. * has asplenia or failure to thrive. adults: - is breastfeeding.
quality control of ce-certified phonak hearing aids - 2018_07

Conditions: Hearing Loss, Sensorineural

Summary: phonak hearing systems pass through different development and study stages. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. afterwards, and prior to product launch, the phonak hearing systems undergo a final quality control in terms of clinical trials. this is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. this will be a clinical evaluation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).


Eligibility criteria:
inclusion criteria: * adult hearing impaired persons (minimum age: 18 years) with or without experience with hearing aids * good written and spoken (swiss) german language skills * healthy outer ear * ability to fill in a questionnaire (p/ecrf) conscientiously * willingness to wear custom made hearing aids * informed consent as documented by signature * benefit with tfg tool at least on one ear exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result * limited dexterity (not able to change a 10size hearing aid battery) * no benefit of the tfg tool on both ears * known psychological problems * central hearing disorders
compare the diuretic effect with furosemide vs furosemide and albumin combined in cirrhotic patients

Conditions: Cirrhosis, Liver; Volume Overload; Fluid Overload

Summary: a common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis. the cause of this diuretic resistance is hypothesized to be secondary to hypoalbuminemia which has led some providers to give human albumin in combination with loop diuretics to increase intravascular volume and facilitate diuresis. however, this practice remains controversial because minimal data exists to support its efficacy. the purpose of this study is to compare the efficacy of diuretics alone versus diuretics in combination with albumin in cirrhotic patients presenting with fluid retention.

the purpose of this single center, prospective study is to compare the efficacy of two strategies for diuresis in patients with cirrhosis, the use of furosemide (lasix®) alone versus the combination of furosemide (lasix ®) and albumin (25%). the investigators will perform a single-center, prospective study with data collected as result of standard of care at rush university medical center (rumc). patients who are 18 years of age and older, have diagnosed cirrhosis, and present to rumc with fluid retention will be identified by the hepatology and/or surgery attending and be screened for inclusion in the study. each patient will be randomized into one of the two cohorts and will have 50% chance of being placed into either cohort. cohort 1 will receive furosemide (lasix) 40 to 80 mg intravenous push (ivp) twice a day (bid) for at least 48 hours and cohort 2 will receive combination of furosemide (lasix) 40 to 80 mg ivp bid and albumin (25%) 12.5 grams bid for at least 48 hours.

Eligibility criteria:
inclusion criteria: * adult patients (age \>18 years old) * diagnosis of cirrhosis * presents with fluid retention as defined as ascites, edema, or pulmonary effusions requiring diuresis. exclusion criteria: * patients who are younger than 18 years of age * patients who are currently pregnant * patients who present with a serum creatinine greater than 2 mg/dl
monitoring of breast cancers treated by neoadjuvant therapy via diffusion-weighted magnetic resonance imaging

Conditions: Breast Cancer

Summary: magnetic resonance imaging (mri) is the method of choice in breast cancer to perform the loco-regional staging and direct the treatment. european guidelines (eusoma) currently recommend mri for initial evaluation and assessement of the neoadjuvant chemotherapy (nac) response, for breast cancer. the standard of care consists of realizing a mri before the start of the nac and another one after it's ended, six months later. there is currently no consensus on the realization of an interval mri for early assessment of the chemosensitivity of the tumor. it would allow though alterations in the therapeutic regimen in the event of a non response. similarly, there is no consensus on when this interval mri should be performed. some recent studies suggest that diffusion-weighted magnetic resonance imaging is interesting for the evaluation of the early response. however, these are preliminary studies with quantitative measures realized by the region of interest (roi) method. a response to neoadjuvant chemotherapy results in elevated values of apparent diffusion coefficients (adc). the investigator's goal for this study is to evaluate the reliability of diffusion as tumor biomarker. therefore, they will study the quantitative analysis of the diffusion-weighted magnetic resonance sequences in the pre-therapeutic assessment and the early and late follow-up of breast cancers under neoadjuvant treatment (chemotherapy, hormonotherapy...) within the chu brugmann hospital. the results of this analysis will be compared with the mri results obtained at the end of the treatment and with the histology of the initial biopsy and the surgical specimen. the expected benefits are: * to establish correlations between apparent diffusion coefficients (adc) values and histology * to observe changes in the adc according to the type of response: adc increase in the event of partial response, adc stability in the event of non response, adc decrease in the event of a progression, absence of restriction in the event of a complete response. * to confirm that diffusion weighted mri within a short interval (after one cure, at one month) has a predictive value for the neoadjuvant chemotherapy (nac) response.


Eligibility criteria:
inclusion criteria: * breast cancer * neo-adjuvant therapy indication * performance status from 0 to 2 exclusion criteria: * contraindications to magnetic resonance imaging (pacemaker, nerve stimulator, cochlear implant, major claustrophobia) * absence of histological results * disruption of the neo-adjuvant therapy

Keywords: diffusion weighted magnetic resonance imaging breast cancer neo-adjuvant therapy
combined effects of percussion with diaphragmatic breathing exercises on airway clearance in elderly pneumonia patients

Conditions: Pneumonia

Summary: the group a will receive percussions and diaphragmatic breathing with 1 session a day for 3 days in a week for 4 weeks. in this way total 12 sessions will be given to the patients. and group b will receive only diaphragmatic breathing with 1 session a day for total 3 days in a week for 4 weeks. by this intervention procedure, i will find out the effects of these techniques on airway clearance of the pneumonia patients, their effect on the quality of life and on dyspnea. for this i will use 4 tool questionnaires that are 1-bcss, 2- modified borg dyspnea scale, 3-rate of perceived exertion scale, 4- health-related quality of life-14. bcss will be used to assess breathlessness, cough and sputum retention. modified borg dyspnea scale is 0-10 rated numerical scale used to measure dyspnea. rpe is a way to measure the level of exertion a person feels during physical activity. hrqol-14 will assess the quality of life of the pneumonia patients.

it will be a randomized clinical trial. and the data will be conducted from mayo hospital lahore. convenient sampling technique will be applied on patients according to the inclusion criteria. patients will be allocated through simple random sampling into group a and group b to collect data. for this purpose, i will divide my sample size into two groups. the group a will receive percussions and diaphragmatic breathing with 1 session a day for 3 days in a week for 4 weeks. in this way total 12 sessions will be given to the patients. and group b will receive only diaphragmatic breathing with 1 session a day for total 3 days in a week for 4 weeks. by this intervention procedure, i will find out the effects of these techniques on airway clearance of the pneumonia patients, their effect on the quality of life and on dyspnea. for this i will use 4 tool questionnaires that are 1-bcss, 2- modified borg dyspnea scale, 3-rate of perceived exertion scale, 4- health-related quality of life-14. bcss will be used to assess breathlessness, cough and sputum retention. modified borg dyspnea scale is 0-10 rated numerical scale used to measure dyspnea. rpe is a way to measure the level of exertion a person feels during physical activity. hrqol-14 will assess the quality of life of the pneumonia patients. before and after each session, the primary and secondary outcomes will be measured for both groups. after collecting the data, the data will be analyzed by using spss version 25.

Eligibility criteria:
inclusion criteria: * patients aged 40-60, * both males and females * those patients who will be vitally stable (oxygen saturation, respiratory rate) * pneumonia diagnosed patients (community acquired pneumonia) exclusion criteria: * patients with heart disease * patients with neurological disorders such as: alzheimer, epilepsy, parkinson disease * patients with orthopedic conditions * other pulmonary complications (atelectasis, diaphragmatic injury, ards)

Keywords: cap, diaphragmatic breathing, percussion and pneumonia